Want to join the conversation?
$WBA said that in the Pharmaceutical Wholesale division, comparable sales on a constant currency basis, excluding acquisitions and dispositions rose by 6.3%. $WBA's operating cash flow was $2.1Bil in 3Q16, helped by the solid profit performance and favorable working capital cash flows. Free cash flow for the quarter was $1.9Bil.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.